Moderna
Moderna
MRNA
NASDAQ
37.29
USD
-6.24%
About
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators.
mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development.
Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 3.5M |
| Three Month Average Volume | 79.5M |
| High Low | |
| Fifty-Two Week High | 170.47 USD |
| Fifty-Two Week Low | 62.55 USD |
| Fifty-Two Week High Date | 24 May 2024 |
| Fifty-Two Week Low Date | 02 Nov 2023 |
| Price and Volume | |
| Current Price | 77.4 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | -15.38% |
| Thirteen Week Relative Price Change | -49.27% |
| Twenty-Six Week Relative Price Change | -25.95% |
| Fifty-Two Week Relative Price Change | -45.37% |
| Year-to-Date Relative Price Change | -34.28% |
| Price Change | |
| One Day Price Change | -0.24% |
| Thirteen Week Price Change | -45.70% |
| Twenty-Six Week Price Change | -18.58% |
| Five Day Price Change | -6.11% |
| Fifty-Two Week Price Change | -31.55% |
| Year-to-Date Price Change | -22.17% |
| Month-to-Date Price Change | -35.08% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 36.26702 USD |
| Book Value Per Share (Most Recent Quarter) | 30.5 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 36.01571 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 30.25521 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -6.44081 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 17.9267 USD |
| Revenue Per Share (Trailing Twelve Months) | 13.21125 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -12.34031 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -15.36615 USD |
| Normalized (Last Fiscal Year) | -8.59686 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -12.34031 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -15.36615 USD |
| Including Extraordinary Items (Last Fiscal Year) | -12.34031 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -15.36615 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 22.52356 USD |
| Cash Per Share (Most Recent Quarter) | 22.10417 USD |
| Cash Flow Per Share (Last Fiscal Year) | -10.71466 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -13.96468 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -10.40942 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | 34 |
| Cash Flow Revenue (Trailing Twelve Months) | -79 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -85.78% |
| Pretax Margin (Last Fiscal Year) | -57.56% |
| Pretax Margin (5 Year) | 38.86% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 63.60% |
| Gross Margin (Trailing Twelve Months) | 65.60% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -61.90% |
| Operating Margin (Trailing Twelve Months) | -91.78% |
| Operating Margin (5 Year) | 37.78% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -68.84% |
| Net Profit Margin (Trailing Twelve Months) | -116.18% |
| Net Profit Margin (5 Year) | 32.10% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 50.78% |
| Tangible Book Value (5 Year) | 55.15% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -29.94% |
| Revenue Growth (3 Year) | 119.28% |
| Revenue Change (Trailing Twelve Months) | -52.60% |
| Revenue Per Share Growth | 112.80% |
| Revenue Growth (5 Year) | 104.27% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 46.22% |
| Total Debt (5 Year) | 76.58% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 8.04% |
| EPS Change (Trailing Twelve Months) | -668.26% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 2 |
| Price to Tangible Book (Most Recent Quarter) | 3 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -7,912,000,000 |
| Net Debt (Last Fiscal Year) | -8,029,000,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 4 |
| Price to Sales (Trailing Twelve Months) | 6 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 104 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 4 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 2 |
| Price to Book (Most Recent Quarter) | 3 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 4 |
| Long Term Debt to Equity (Most Recent Quarter) | 5 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 3 |
| Quick Ratio (Most Recent Quarter) | 4 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 3 |
| Current Ratio (Most Recent Quarter) | 4 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -3,825,000,000 |
| Free Cash Flow (Trailing Twelve Months) | -3,979,000,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 4 |
| Total Debt to Equity (Most Recent Quarter) | 5 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -21.29% |
| Return on Assets (Trailing Twelve Months) | -31.24% |
| Return on Assets (5 Year) | 20.95% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -28.59% |
| Return on Equity (Trailing Twelve Months) | -40.94% |
| Return on Equity (5 Year) | 32.64% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -25.94% |
| Return on Investment (Trailing Twelve Months) | -36.58% |
| Return on Investment (5 Year) | 29.51% |